Separately, Northland Securities reiterated a buy rating on shares of Motif Bio in a research note on Friday, September 28th.
MTFB opened at GBX 33.46 ($0.44) on Monday. Motif Bio has a 52-week low of GBX 23.50 ($0.31) and a 52-week high of GBX 51.75 ($0.68).
About Motif Bio
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
Further Reading: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.